<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Guidelines</title>

        <link href="../jquery-mobile/jquery.mobile.theme-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.2.0.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.8.2.min.js" type="text/javascript"></script>
        <script src="../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.2.0.min.js" type="text/javascript"></script>
        <script src="../cordova-2.2.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>

    </head>
    <body>

        <!-- Start of page -->
        <div data-role="page" id="heading_page_273" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-272.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Guidelines</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>  <!-- end of header div -->

            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-262.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-272.html" >Diseases Characterized by Vaginal Discharge</a><span class="carrot"> > </span>
                    <a href="lv-272.html" >Trichomoniasis</a><span class="carrot"> > </span>Follow-Up
            </div>   <!-- end of guidelines listview breadcrumbs -->
            </br><h3 class="sgc-1" id="sigil_toc_id_273">
 Follow-Up
</h3>
<p>
 Because of the high rate of reinfection among patients in whom trichomoniasis was diagnosed (17% were reinfected within 3 months in one study), rescreening for
 <i>
  T. vaginalis
 </i>
 at 3 months following initial infection can be considered for sexually active women with trichomoniasis; the benefit of this approach, however, has not been fully evaluated (64). No data support rescreening in men diagnosed with
 <i>
  T. vaginalis
 </i>
 . While most recurrent
 <i>
  T. vaginalis
 </i>
 infections are thought to result from having sex with an untreated partner (i.e., reinfection), some&nbsp;recurrent cases can be attributed to diminished susceptibility to metronidazole. Low-level metronidazole resistance has been identified in 2%&ndash;5% of cases of vaginal trichomoniasis (362,363), but high-level resistance only rarely occurs. Fortunately, infections caused by most of these organisms respond to tinidazole or higher doses of metronidazole. Tinidazole has a longer serum half-life and reaches higher levels in genitourinary tissues than metronidazole. In addition, many
 <i>
  T. vaginalis
 </i>
 isolates have lower minimal lethal concentrations (MLCs) to tinidazole than metronidazole.
</p>
<p>
 If treatment failure occurs with metronidazole 2-g single dose and reinfection is excluded, the patient can be treated with metronidazole 500 mg orally twice daily for 7 days. For patients failing this regimen, treatment with tinidazole or metronidazole at 2 g orally for 5 days should be considered. If these therapies are not effective, further management should be discussed with a specialist. The consultation should ideally include determination of the susceptibility of
 <i>
  T. vaginalis
 </i>
 to metronidazole and tinidazole. Consultation and
 <i>
  T. vaginalis
 </i>
 susceptibility testing is available from CDC (telephone: 404-718-4141; website:
 <a href="http://www.cdc.gov/std" rel="external" target="_blank">
  http://www.cdc.gov/std
 </a>
 ).
</p>

            </div>
            <script type="text/javascript">

                $('div').live('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView("273");
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

    